Calidi Biotherapeutics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Calidi Biotherapeutics, Inc. (CLDI) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $157.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-13
- Calidi Biotherapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $157.00K, a 69.92% decline year-over-year.
- Calidi Biotherapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $231.00K, a 61.94% decline year-over-year.
- Calidi Biotherapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $529.00K, a 23.44% decline year-over-year.
- Calidi Biotherapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $522.00K, a 30.49% decline year-over-year.
- Calidi Biotherapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $2.11M, a 28.71% decline from fiscal 2024.
- Calidi Biotherapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $2.96M, a 38.51% decline from fiscal 2023.
- Calidi Biotherapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $4.81M, a 6.35% increase from fiscal 2022.
- Calidi Biotherapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $4.52M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $157.00K 10-Q · filed 2026-08-13 | $388.00K derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $231.00K 10-Q · filed 2026-08-13 | |||
| 2025-12-31 | $2.11M 10-K · filed 2026-03-27 | |||
| 2025-09-30 | $529.00K 10-Q · filed 2025-11-13 | $1.05M derived: sum of 2 quarters · filed 2026-08-13 | $1.66M derived: sum of 3 quarters · filed 2026-08-13 | |
| 2025-06-30 | $522.00K 10-Q · filed 2026-08-13 | $1.13M derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $607.00K 10-Q · filed 2026-08-13 | |||
| 2024-12-31 | $2.96M 10-K · filed 2026-03-27 | |||
| 2024-09-30 | $691.00K 10-Q · filed 2025-11-13 | $1.44M derived: sum of 2 quarters · filed 2025-11-13 | $2.33M derived: sum of 3 quarters · filed 2025-11-13 | |
| 2024-06-30 | $751.00K 10-Q · filed 2025-11-13 | $1.64M derived: sum of 2 quarters · filed 2025-11-13 | ||
| 2024-03-31 | $888.00K 10-Q · filed 2025-11-13 | |||
| 2023-12-31 | $4.81M 10-K · filed 2025-03-31 | |||
| 2023-09-30 | $1.11M 10-Q · filed 2024-11-12 | $2.19M derived: sum of 2 quarters · filed 2024-11-12 | $3.62M derived: sum of 3 quarters · filed 2024-11-12 | |
| 2023-06-30 | $1.08M 10-Q · filed 2024-11-12 | $2.51M derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2023-03-31 | $1.43M 10-Q · filed 2024-11-12 | |||
| 2022-12-31 | $4.52M 10-K · filed 2024-03-15 | |||
| 2022-09-30 | $1.06M 10-Q · filed 2023-11-14 | $2.00M derived: sum of 2 quarters · filed 2023-11-14 | ||
| 2022-06-30 | $936.00K 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |